Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 1

2(33.3%)

6Total

N/A(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03957707Not ApplicableActive Not Recruiting

Sterotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation

Role: collaborator

NCT06459167Not ApplicableNot Yet Recruiting

Position Intervention to Reduce Hypoxemia in Sedation Patients

Role: collaborator

NCT04915690Unknown

Investigation on the Practice Status of Emergency Stuff

Role: collaborator

NCT03778346Phase 1Unknown

Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

Role: lead

NCT03932565Phase 1Unknown

Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors

Role: lead

NCT04373395Not ApplicableUnknown

Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Role: collaborator

NCT04130984Not ApplicableUnknown

Intraosseous Versus Intravenous Vascular Access During Resuscitation Following Out-of-Hospital Cardiac Arrest

Role: collaborator

All 7 trials loaded